US0352551081
US0352551081
Anika Therapeutics Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 112.819.000 | 119.907.000 | 5.9% |
| Cost of Revenue | 49.012.000 | 43.909.000 | 11.6% |
| Gross Profit | 63.807.000 | 75.998.000 | 16.0% |
| 74.858.000 | 81.099.000 | 7.7% | |
| Operating Income | -11.051.000 | -5.101.000 | 116.6% |
| Pretax Income | -9.307.000 | -2.764.000 | 236.7% |
| Net Income Common Stockholders | -10.880.000 | -56.385.000 | 80.7% |
| -- | -- | -- | |
| -- | -- | -- |